Publications by authors named "M B Feinstein"
Cardiovascular adverse events (CVAEs) are recognized complications of chimeric antigen receptor (CAR) T-cell therapies. However, data are lacking regarding subtypes of adverse events that develop in patients with different malignancies, and little is known about the timeframe in which different cardiotoxicities are most likely to occur post-CAR T-cell therapies. In this study, 211 patients, including 138 lymphoma patients and 66 myeloma patients who received CAR T-cell therapies were retrospectively identified.
View Article and Find Full Text PDFArticle Synopsis
- Findings indicate that higher cumulative HIV viral load (VL) and lower CD4 cell counts are significantly linked to an increased risk of developing venous thromboembolism (VTE) in people living with HIV (PWH).
- A study involving over 21,000 PWH over nearly five years revealed that those with higher cumulative VL had a 45% increased risk of VTE compared to those with lower VL. Additionally, a CD4 count below 100 cells/mm³ was associated with a fourfold increase in risk.
- The research suggests that managing HIV viral load and maintaining CD4 levels could be crucial strategies to lower the risk of VTE in PWH.
Background: Few data exist on myocardial fibrosis and inflammation in youth with HIV.
Methods: We performed cardiovascular magnetic resonance (CMR) on a cross section of South African youth: youth with perinatally acquired HIV (YPHIV) undergoing antiretroviral therapy (ART), youth with nonperinatally acquired HIV (YNPHIV) receiving ART, and youth without HIV. Quantile regression models were fit to assess the association between HIV status and CMR outcomes: subclinical fibrosis (late gadolinium enhancement [LGE] mass and fraction, native T1, extracellular volume) and inflammation (native T1, T2 mapping).
Objective: We assessed the association of early statin initiation with inpatient mortality among hospitalised COVID-19 patients.
Design, Setting And Participants: This observational study emulated a hypothetical target trial using electronic health records data from Northwestern Medicine Health System, Illinois, 2020-2022. We included patients who were ≥40 years, admitted ≥48 hours for COVID-19 from March 2020 to August 2022 and had no evidence of statin use before admission.
Background: A consequence of improved survival of people living with human immunodeficiency virus (HIV) (PLHIV) is an aging population with an increased risk of developing atherosclerotic cardiovascular diseases (ASCVDs). International guidelines recommend primary preventive strategies which should be integrated into routine care of PLHIV.
Aims: This study audited the ASCVD preventive practices offered to PLHIV at the adult antiretroviral clinic in Ibadan.